Follow
claudio micheletto
claudio micheletto
Direttore UOC Pneumologia, Azienda Ospedaliera Universitaria Integrata - Verona
Verified email at univr.it
Title
Cited by
Cited by
Year
Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients
AM Riccio, RW Dal Negro, C Micheletto, L De Ferrari, C Folli, A Chiappori, ...
International journal of immunopathology and pharmacology 25 (2), 475-484, 2012
1452012
Comprehensive effects of supplemented essential amino acids in patients with severe COPD and sarcopenia
RW Dal Negro, R Aquilani, S Bertacco, F Boschi, C Micheletto, S Tognella
Monaldi archives for chest disease 73 (1), 2010
922010
Comorbidities, cardiovascular therapies, and COVID-19 mortality: a nationwide, Italian observational study (ItaliCO)
F Polverino, DA Stern, G Ruocco, E Balestro, M Bassetti, M Candelli, ...
Frontiers in cardiovascular medicine 7, 585866, 2020
812020
Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial Inflammation
R Dal Negro, C Micheletto, S Tognella, M Visconti, C Turati
Advances in therapy 25, 1019-1030, 2008
792008
Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial Inflammation
R Dal Negro, C Micheletto, S Tognella, M Visconti, C Turati
Advances in therapy 25, 1019-1030, 2008
792008
Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues
A Roggeri, C Micheletto, DP Roggeri
International Journal of Chronic Obstructive Pulmonary Disease, 597-602, 2016
772016
Salmeterol & Fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with …
RW Dal Negro, C Pomari, S Tognella, C Micheletto
Pulmonary pharmacology & therapeutics 16 (4), 241-246, 2003
762003
Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months
AM Riccio, P Mauri, L De Ferrari, R Rossi, D Di Silvestre, L Benazzi, ...
Clinical and translational allergy 7, 1-10, 2017
732017
Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD
RW Dal Negro, M Visconti, C Micheletto, S Tognella
Pulmonary pharmacology & therapeutics 21 (2), 304-308, 2008
662008
Determinants of persistence of symptoms and impact on physical and mental wellbeing in Long COVID: A prospective cohort study
E Righi, M Mirandola, F Mazzaferri, G Dossi, E Razzaboni, A Zaffagnini, ...
Journal of Infection 84 (4), 566-572, 2022
602022
Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity
M Caminati, A Vultaggio, A Matucci, G Senna, F Almerigogna, ...
Respiratory Medicine 176, 106261, 2021
562021
Small airway dysfunction and bronchial asthma control: the state of the art
M Cottini, C Lombardi, C Micheletto
Asthma research and practice 1 (1), 1-11, 2015
552015
Asthmatic patients in COVID-19 outbreak: few cases despite many cases
M Caminati, C Lombardi, C Micheletto, E Roca, B Bigni, F Furci, D Girelli, ...
Journal of Allergy and Clinical Immunology 146 (3), 541-542, 2020
532020
Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA‐sensitive asthmatics: a controlled study vs placebo
C Micheletto, S Tognella, M Visconti, C Pomari, F Trevisan, RW Dal Negro
Allergy 59 (3), 289-294, 2004
512004
Severe asthma in adults does not significantly affect the outcome of COVID‐19 disease: results from the Italian Severe Asthma Registry
L Antonicelli, C Tontini, G Manzotti, L Ronchi, A Vaghi, F Bini, ...
Allergy 76 (3), 902, 2021
492021
Prevalence of tracheobronchomalacia and excessive dynamic airway collapse in bronchial asthma of different severity
RW Dal Negro, S Tognella, M Guerriero, C Micheletto
Multidisciplinary Respiratory Medicine 8, 1-5, 2013
482013
Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy
RW Dal Negro, L Pradelli, S Tognella, C Micheletto, S Iannazzo
European annals of allergy and clinical immunology 43 (2), 45, 2011
462011
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: results from a multicenter Italian survey
A Matucci, M Caminati, E Vivarelli, A Vianello, C Micheletto, F Menzella, ...
Allergy 76 (3), 871-874, 2021
442021
Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and-intolerant asthmatics
C Micheletto, S Tognella, M Visconti, F Trevisan, RW Dal Negro
Respiratory medicine 100 (12), 2144-2150, 2006
412006
Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience
M Caminati, G Senna, G Stefanizzi, R Bellamoli, S Longhi, ...
BMC Pulmonary Medicine 16, 1-9, 2016
402016
The system can't perform the operation now. Try again later.
Articles 1–20